CMC Project Leader
About the job
- A Bachelor's degree in Science with Chemistry, Biochemistry, Bioengineering, or a similar field is required.
- A Master's degree in Science with Chemistry, Biochemistry, Bioengineering, or a similar field is referred.
- A minimum of 6 years of experience in the biopharmaceutical, contract development and manufacturing organization, or chemical industry is required with a bachelor's degree.
- A minimum of 4 years of experience in the biopharmaceutical, contract development and manufacturing organization, or chemical industry is required with a master's degree.
- A minimum of 2 years of experience in a customer-facing role or chemistry, manufacturing, and controls project management is required.
- Basic knowledge of clinical development phases, key goals, requirements, and associated regulatory compliance and filings for drug substances is required.
- Basic understanding of good manufacturing practices is required.
- Ability to understand financial aspects of customer accounts, including payment terms, pre-payment requirements, and forecasting.
- Familiarity with drug substance characterization analysis, including high-performance liquid chromatography, ultra-performance liquid chromatography, liquid chromatography-mass spectrometry, mass spectrometry, gas chromatography-mass spectrometry, amino acid analysis, and carbon-hydrogen-nitrogen analysis, for in-process, release, and stability testing.
- Excellent computer and system skills, especially Microsoft Office, customer relationship management systems such as Salesforce, document control systems such as MasterControl, document-sharing platforms such as SharePoint and ShareFile, enterprise resource planning systems such as SAP, and Microsoft Project.
- Ability to organize and multitask effectively in a fast-paced, deadline-driven environment.
- Proactive, solution-focused communication skills to ensure management and stakeholders are informed of potential issues.
- Detail orientation and strong problem-solving skills, with the ability to work independently and manage time efficiently.
- Ability to communicate and collaborate effectively in cross-functional team settings.
- Knowledge of chemistry, manufacturing, and controls documents related to investigational new drug and new drug application filings and active pharmaceutical ingredient development.
- Knowledge of contracts and agreements, including nondisclosure agreements, supply agreements, quality agreements, and requests for proposals, to ensure adherence during project execution.
- Lead project teams of 3 to 10 internal members and additional external members for customers and in-house research and development operations.
- Act as the business lead in ongoing collaborations, including contract negotiation, business proposals, forecasting, and risk-sharing options.
- Ensure adherence to project scope and achievement of deliverables on time while considering customer agreements and contracts.
- Serve as the point of contact for project-related tasks, questions, and issues in line with the roles and responsibilities defined in the project management guide.
- Structure, lead, and monitor activities with project team members using available tools and systems.
- Represent Bachem in project-related interactions with senior and executive leadership of Bachem's customers.
- Report accurate project data in customer relationship management and document exchange platforms such as Salesforce and Teams.
- Partner with Bachem senior and executive leadership to secure necessary capacity and support for customer projects.
- Compile accurate, fit-for-purpose documentation, including minutes, plans, actions, summaries, and strategic options, using existing templates.
- Identify opportunities to expand the scope of existing collaborations and present them to customers with the goal of generating additional business.
- A Master's degree in Business Administration, Project Management Professional certification, or a similar certification is preferred.
- A PhD in Science with Chemistry, Biochemistry, Bioengineering, or a similar field is preferred.
- Experience with different types of customers, including small biotechnology companies and large customers, with a basic understanding of good manufacturing practices is preferred.
- Project Management Professional certification from the Project Management Institute is preferred.
About the company
Bachem provides development and manufacturing of peptides and oligonucleotides for research, clinical development, and commercial products. Its offerings include custom synthesis and scale-up production, analytical testing, and related services across the drug development spectrum. Customers work with Bachem by specifying desired sequences and specifications, after which Bachem designs, synthesizes, and quality-controls the peptides or oligonucleotides and delivers them in appropriate scales and formats. The company differentiates itself through more than five decades of experience, a global footprint with sites in Europe, the US, and Asia, and an integrated set of services spanning discovery support to commercial manufacturing. Its goal is to help pharmaceutical and biotechnology companies advance peptide- and oligonucleotide-based therapies by providing reliable, scalable, and well-supported manufacturing and development capabilities.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Bubendorf, Switzerland
Founded
1971
Get referred to Bachem
See people who can refer or advise you
Simplify's Take
What believers are saying
- H1 2026 sales rose 4.3% to CHF326.4 million, with 7.3% local-currency growth.
- Bachem reaffirmed 2026 sales growth of 35%-40% in local currencies.
- Claros' September 2026 PFAS pilot could lower wastewater compliance costs and regulatory exposure.
What critics are saying
- Basel-Landschaft TFA contamination scrutiny intensifies after September 2026 reporting and activism.
- Bachem's 2026 EBITDA margin fell to 25.4% from Building K ramp-up costs.
- Sisslerfeld's 2030 start leaves multi-year execution risk before returns arrive.
What makes Bachem unique
- Bachem is the peptide and oligonucleotide specialist behind GLP-1 API supply.
- Sisslerfeld's CHF500 million+ plant secures long-term peptide capacity beyond 2030.
- Building K began commercial GMP production in 2026, proving large-scale execution.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Growth & Insights and Company News
6 month growth
↑ 24%1 year growth
↑ 24%2 year growth
↑ 24%CDMOs are investing billions in European API capacity. Companies are responding to risks related to demand and supply chains. 24-Sep-2026 contract development and manufacturing organizations (CDMOs) are ramping up their active pharmaceutical ingredient (API) investments in Europe. A series of recent deals shows how companies are strengthening their infrastructure in the region, as they position themselves to develop and supply newer, more complex medicines, says GlobalData, a leading intelligence and productivity platform. GlobalData's monthly Bio/Pharmaceutical Outsourcing report reveals that the expansion of CDMO API capacity in Europe is taking place across several stages of the pharmaceutical value chain and has two main drivers: evolving demand and sensitive supply chains. Edita Hamzic, Healthcare Analyst at GlobalData, says: "Demand is changing. GLP-1s, peptides, biologics and other advanced therapies require more specialized manufacturing than many traditional medicines. Supply chains have become more sensitive to disruption risks; building capacity closer to European customers can provide greater supply security." There were four API investments between July and August 2026. The largest commitment comes from Bachem, the Swiss peptide and oligonucleotide CDMO, which plans to invest more than CHF500 million (about $609 million) in a new large-scale production facility at Sisslerfeld in Eiken, Switzerland, its third Swiss site. The main driver is demand for peptide APIs, particularly the rapid growth of metabolic medicines such as GLP-1 drugs for obesity and diabetes. Cambrex is investing $30 million in a new R&D facility at its Milan site. The project will add analytical development and process R&D capabilities and upgrade existing production plants, with completion expected in H2 2027. Cambrex has also acquired adjacent land for future expansion. The investment will support the earlier stages of drug development and strengthen Cambrex's ability to develop and scale complex small-molecule APIs before they reach commercial production. Théa Group and Unither Pharmaceuticals are developing a 20,000-square-meter facility in Gannat, France, with an investment of more than EUR140 million (about $161 million). Unlike a typical CDMO facility serving multiple customers, this site will be primarily dedicated to manufacture Théa's sterile ophthalmic products for the French and wider European markets. The facility expands Théa's European manufacturing capacity and supports its long-term growth. Meanwhile, German pharma group Merck, which provides CDMO services on an 'excess capacity' basis, has opened a EUR25 million (about $29 million) BioReliance testing facility in Darmstadt, Germany. The 2,000-square-meter site provides drug-substance and drug-product release testing and GMP-compliant stability studies for monoclonal antibodies and cell therapies for the company's biopharmaceutical customers. Hamzic concludes: "In addition to their importance to the companies concerned, the investments also have a strategic dimension for Europe as a whole. They will build specialized skills and jobs, strengthen pharmaceutical networks, and reduce the region's dependence on outside manufacturing capacity."
Claros Technologies has completed a successful pilot of its ClarosTechUV™ PFAS destruction system at Bachem AG's Swiss manufacturing facility in Bubendorf. The two-week trial marks Claros's entry into pharmaceutical manufacturing and European expansion. Bachem, a leading manufacturer of peptide and oligonucleotide active pharmaceutical ingredients, including those used in GLP-1 therapies, tested the system under real-world conditions. The technology permanently destroys trifluoroacetic acid (TFA), an ultra-short-chain PFAS facing increasing regulatory scrutiny in Europe and the US. Unlike conventional treatment methods that create secondary waste streams, ClarosTechUV™ uses a proprietary UV photochemical process to eliminate PFAS at the source. Following treatment, only very low residual TFA concentrations remained detectable in Bachem's industrial wastewater. The Minneapolis-based company, founded in 2018, says its system destroys 99.99% of target PFAS species across long, short, and ultra-short chains.
Bachem stock holds steady with focus on peptide manufacturing. Published on 09/06/2026 at 18:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Bachem stock reflects investor interest in peptide-based pharmaceuticals as the company continues to expand its manufacturing capabilities for biotech and pharma customers. Bachem stock represents exposure to a specialized player in peptide and oligonucleotide manufacturing for the global pharmaceutical and biotechnology industry. The Swiss group (ISIN CH0012530207) has built its business around supplying active pharmaceutical ingredients and research-grade materials that underpin many modern therapies. Peptide manufacturing as a core business. Bachem focuses on the development and large-scale production of synthetic peptides and related molecules that are used as active ingredients in drugs as well as in preclinical and clinical research. For investors, this means the company's fortunes are closely tied to progress in peptide-based therapeutics and to long-term supply agreements with pharma partners. In recent years, the broader market for peptide medicines has grown as more drug makers pursue highly targeted treatments, for example in metabolic diseases, oncology and rare conditions. Bachem has responded by expanding capacity, investing in new plants and process technologies, and positioning itself as a strategic partner for both large pharma and emerging biotech customers. Operational scale and customer base. The company operates multiple production sites in Europe and North America, which allows it to supply customers across different regions and manage regulatory requirements in major markets. Its customer base typically includes large pharmaceutical companies, generic drug producers and specialized biotech firms that rely on a steady, high-quality supply of complex peptide ingredients. Because peptide synthesis is technically demanding and subject to strict quality standards, Bachem's ability to run efficient, compliant manufacturing at scale is central to its competitive position. The group's pipeline of customer projects and the mix between commercial APIs and research services are key drivers for revenue and profitability over time. More on Bachem as an investment. Further articles and regulatory disclosures help investors follow how Bachem stock reacts to new contracts, capacity expansions and financial results. Representative product: peptide active ingredients. One representative area of Bachem's portfolio is the supply of peptide active pharmaceutical ingredients manufactured under strict good manufacturing practice standards. These ingredients are used in approved medicines and in clinical-stage compounds, making reliability and regulatory compliance crucial for customers. Stock as a way to participate. For investors, Bachem stock offers a way to participate in the long-term growth of peptide-based therapies and in the company's role as a specialized contract manufacturer. The stock is typically traded on Swiss exchanges and reflects expectations about future demand for complex peptide ingredients and the company's ability to translate that demand into stable revenue and earnings. Bachem at a glance. * Company: Bachem Holding AG * ISIN: CH0012530207 * Ticker: BACN * Trading venue: SIX Swiss Exchange * Sector / Industry: Health Care / Pharmaceuticals * Index membership: SPI Follow Bachem on social platforms. Sponsored Ad Bachem stock: new analysis - 15 september. Fresh Bachem information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | CH0012530207 | BACHEM | boerse | 70060733 | bgmi
Bachem case study presents new method for verifying oligonucleotide peak purity. news-releases Bachem AG August 26th 2026 Bubendorf, Switzerland - A new case study from leading CDMO Bachem details a two-dimensional liquid chromatography-mass spectrometry workflow for verifying the purity of oligonucleotide peaks separated by strong anion exchange (SAX) chromatography. The workflow combines SAX fraction collection with mass spectrometry-compatible ion-pair reversed-phase (IP-RP) chromatography, enabling potential co-eluting impurities within apparently pure SAX peaks to be identified. Overcoming an analytical challenge. This latest advance forms part of Bachem's continuing drive toward more accurate analytical characterization throughout oligonucleotide development. It supports impurity profiling and stability assessment, ultimately contributing to the delivery of high-quality active pharmaceutical ingredients (APIs). Strong anion exchange liquid chromatography and mass spectrometry are two powerful analytical tools for characterizing oligonucleotides. SAX is widely used as an orthogonal method to support the purity assessment of oligonucleotide APIs because it separates analytes differently from IP-RP chromatography. However, the non-volatile salts used in SAX mobile phases prevent direct coupling to mass spectrometry. This makes it difficult to determine whether a seemingly pure UV-detected peak contains co-eluting impurities. 2D SAX-IP-RP-MS workflow. To address this analytical challenge, Bachem has developed a two-dimensional SAX-IP-RP-MS workflow. Bachem describes this as the first method to bring mass spectrometric detection to SAX-separated material, making it possible to verify the peak purity achieved by a SAX method. The workflow involves collecting individual SAX fractions and reanalyzing them using MS-compatible IP-RP chromatography. This enables MS-based assessment of peak purity and provides additional confidence in SAX method performance. siRNA case study. The case study demonstrates the application of the method to a representative duplex small interfering RNA (siRNA) API. The workflow was used to evaluate SAX main peaks that would have been classified as pure based on UV detection alone. The paper explains: * Why UV detection alone may not be sufficient to confirm the purity of SAX main peaks and how co-eluting impurities can remain undetected * How the 2D SAX-IP-RP-MS workflow enables MS-based evaluation of SAX peak purity * How the workflow was applied to a duplex siRNA, revealing PS | PO, methylation, and des-/endo- species beneath the antisense SAX main peak * Why the method is positioned as a development and verification tool that strengthens the routine release strategy without changing it * How 2D SAX-IP-RP-MS fits within Bachem's broader analytical capabilities for oligonucleotide development programs The case study can be downloaded from the Bachem Knowledge Hub via the link under Resources. About Bachem. Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has more than 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. Resources. Case study. Pushing the Boundaries - MCSGP for efficiency and sustainability FREE DOWNLOAD Bachem AG. Contact Information Address: Hauptstrasse 144, 4416, Bubendorf, Switzerland Telephone No: +41 58 595 2021 Contact Bachem AG. Simply fill out the form below to contact Bachem AG now.
Bachem slightly lowers its sales forecast. Abo FuW initial assessment of half-year figures Bachem slightly lowers its sales forecast. The pharmaceutical contract manufacturer recorded 4.3% more revenue in the first half. The jump expected for the second half of the year is now likely to be at the lower end of the previously expected range. Updated 4 hours ago Initial assessment by Rupen Boyadjian at 8:10 a.m. As expected, Bachem grew only modestly in the first half of the year, with revenue rising 4.3% to CHF 326.4 million. In local currencies (LC), growth was +7.3%. Earnings were weighed down by costs for the commissioning of the new production building K for large volumes of peptides. Operating profit at the EBITDA level fell 9% (-4.2% LC) to CHF 82.8 million, but net profit still rose slightly to CHF 50.3 million (H1 2025: CHF 50.1 million).